- Home
- GAME vs INKT Comparison
GAME vs INKT Comparison
Compare GAME & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- INKT
- Stock Information
- Founded
- GAME 2011
- INKT 2017
- Country
- GAME United States
- INKT United States
- Employees
- GAME N/A
- INKT N/A
- Industry
- GAME
- INKT Medicinal Chemicals and Botanical Products
- Sector
- GAME
- INKT Health Care
- Exchange
- GAME Nasdaq
- INKT Nasdaq
- Market Cap
- GAME 27.2M
- INKT 28.8M
- IPO Year
- GAME 2009
- INKT 2021
- Fundamental
- Price
- GAME $1.61
- INKT $23.25
- Analyst Decision
- GAME Strong Buy
- INKT Hold
- Analyst Count
- GAME 3
- INKT 3
- Target Price
- GAME $3.67
- INKT $37.50
- AVG Volume (30 Days)
- GAME 17.4M
- INKT 2.8M
- Earning Date
- GAME 08-13-2025
- INKT 08-12-2025
- Dividend Yield
- GAME N/A
- INKT N/A
- EPS Growth
- GAME N/A
- INKT N/A
- EPS
- GAME N/A
- INKT N/A
- Revenue
- GAME $99,579,536.00
- INKT N/A
- Revenue This Year
- GAME $6.08
- INKT N/A
- Revenue Next Year
- GAME $21.94
- INKT N/A
- P/E Ratio
- GAME N/A
- INKT N/A
- Revenue Growth
- GAME 77.06
- INKT N/A
- 52 Week Low
- GAME $0.50
- INKT $4.56
- 52 Week High
- GAME $2.87
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- GAME 73.77
- INKT 55.18
- Support Level
- GAME $1.37
- INKT $23.11
- Resistance Level
- GAME $2.20
- INKT $76.00
- Average True Range (ATR)
- GAME 0.34
- INKT 7.14
- MACD
- GAME 0.11
- INKT 1.82
- Stochastic Oscillator
- GAME 73.89
- INKT 23.77
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.